Recor Medical CEO and President Lara Barghout [Photo courtesy of Recor Medical]
Recor Medical has some growing to do after winning the first FDA approval for renal denervation (RDN) to treat hypertension.Recor President and CEO Lara Barghout said her company already has somewhere between 300 and 500 employees and plans to hire “across the board” including innovation/R&D, clinical and infrastructure roles.
Barghout — who recently spoke with Medical Design & Outsourcing about how her team beat the world’s largest medical device developers to premarket approval and commercialization of RDN — offered lessons in leadership she’s learned over her career in medtech.
At the time of publication, Recor Medical’s jobs webpage listed open roles in…